Cipla to tap foreign cos for large-scale vax play

Moving beyond a wide portfolio of Covid drugs and diagnostic kits, the Mumbai-based company — with revenues of nearly Rs 20,000 crore — now plans to partner foreign companies for large-scale fill-and-finish services for coronavirus vaccines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3cVydgC
via IFTTT